Equity Profile

VKTX

Viking Therapeutics, Inc.

Health CareBiotechnology$4.4B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-1.00

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal progress in product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VKTX Q2-2026 Earnings Preview

Context

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is significant in the healthcare sector, particularly as the demand for effective treatments in these areas continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

In Q1-2026, Viking reported an EPS of $-1.37, which was significantly worse than the expected $-0.95, leading to a stock drop of 3.27% the following day. This marked a continuation of disappointing earnings surprises for the company.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Viking has consistently missed EPS estimates in recent quarters, raising concerns about its financial stability. Investors are particularly anxious about the company's ability to turn around its earnings.

Bull Case

If Viking can demonstrate improved clinical results or progress in its drug pipeline, it could lead to a positive shift in investor sentiment and stock price.

Bear Case

Continued losses and missed expectations could further erode investor confidence, leading to a significant drop in the stock price.

Key Metrics to Watch

EPS (Earnings Per Share)

$-1.00

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would signal progress in product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it show improvement over previous quarters?

Given the company's history of missing EPS estimates, any signs of improvement could significantly influence investor sentiment.

Is there any update on the progress of Viking's drug pipeline?

Updates on clinical trials or product development can impact future revenue potential and overall market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Viking's potential for a turnaround, as recent clinical trial results could indicate a more favorable outlook than reflected in current estimates.

Supporting Evidence

Options pricing suggests a significant move, indicating that traders expect volatility which may not align with consensus.

The company's recent history of surprises suggests that the market may be overly pessimistic about its recovery potential.

Key Risk

If Viking's drug pipeline shows unexpected positive results, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether Viking can show signs of financial recovery and progress in its drug development efforts.

Bull Confirmed If

A reduction in EPS loss to $-0.80 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.04%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty surrounding the earnings report.

Options are pricing ±26.0% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

44.1%

Calls (506K)P/C Ratio: 0.09Puts (79K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats EPS estimates and provides positive guidance, history suggests a potential stock increase of around 2.79% on the day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors await further clarity.

Miss

If Viking misses EPS estimates again, history suggests the stock could drop by about 0.01% on the day, but the longer-term outlook may worsen.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the clinical trials for Viking's lead drug candidates.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations that could enhance revenue.
4Details on the timeline for upcoming product launches.
5Any changes in regulatory environment that could impact Viking's operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-1.00

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal progress in product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VKTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Viking can demonstrate improved clinical results or progress in its drug pipeline, it could lead to a positive shift in investor sentiment and stock price.

Bear Case

Continued losses and missed expectations could further erode investor confidence, leading to a significant drop in the stock price.

Key Metrics to Watch

EPS (Earnings Per Share)

$-1.00

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would signal progress in product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it show improvement over previous quarters?

Given the company's history of missing EPS estimates, any signs of improvement could significantly influence investor sentiment.

Is there any update on the progress of Viking's drug pipeline?

Updates on clinical trials or product development can impact future revenue potential and overall market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Viking's potential for a turnaround, as recent clinical trial results could indicate a more favorable outlook than reflected in current estimates.

Supporting Evidence

Options pricing suggests a significant move, indicating that traders expect volatility which may not align with consensus.

The company's recent history of surprises suggests that the market may be overly pessimistic about its recovery potential.

Key Risk

If Viking's drug pipeline shows unexpected positive results, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether Viking can show signs of financial recovery and progress in its drug development efforts.

Bull Confirmed If

A reduction in EPS loss to $-0.80 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.04%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty surrounding the earnings report.

Options are pricing ±26.0% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

44.1%

Calls (506K)P/C Ratio: 0.09Puts (79K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats EPS estimates and provides positive guidance, history suggests a potential stock increase of around 2.79% on the day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors await further clarity.

Miss

If Viking misses EPS estimates again, history suggests the stock could drop by about 0.01% on the day, but the longer-term outlook may worsen.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the clinical trials for Viking's lead drug candidates.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations that could enhance revenue.
4Details on the timeline for upcoming product launches.
5Any changes in regulatory environment that could impact Viking's operations.